Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Gynecologic Oncology
Authors: Ning Li, Jianqing Zhu, Rutie Yin, Jing Wang, Lingya Pan, Beihua Kong, Hong Zheng, Jihong Liu, Xiaohua Wu, Li Wang, Yi Huang, Ke Wang, Dongling Zou, Hongqin Zhao, Chunyan Wang, Weiguo Lu, An Lin, Ge Lou, Guiling Li, Pengpeng Qu, Hongying Yang, Xiaoa Zhen, Wenzhao Hang, Jianmei Hou, Lingying Wu
Institutions: University of Chinese Academy of Sciences, West China Second University Hospital of Sichuan University, Hunan Cancer Hospital, Peking Union Medical College Hospital, Qilu Hospital of Shandong University, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center, Fudan University Shanghai Cancer Center, Zhengzhou University, Hubei Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Chongqing University, Chongqing Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, China Medical University, Women's Hospital, School of Medicine, Zhejiang University, Fujian Medical University, Fujian Provincial Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, Wuhan Union Hospital, Huazhong University of Science and Technology, Tianjin Central Hospital of Gynecology Obstetrics, Kunming Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4295225748